Janus Henderson Group PLC Makes New Investment in Alumis Inc. $ALMS

Janus Henderson Group PLC acquired a new stake in Alumis Inc. (NASDAQ:ALMS) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,124,408 shares of the company’s stock, valued at approximately $46,790,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. MPM Bioimpact LLC acquired a new position in shares of Alumis during the fourth quarter worth approximately $23,443,000. Orbimed Advisors LLC bought a new position in shares of Alumis in the 2nd quarter worth $5,779,000. Woodline Partners LP grew its position in Alumis by 809.7% in the 3rd quarter. Woodline Partners LP now owns 1,751,150 shares of the company’s stock valued at $6,987,000 after purchasing an additional 1,558,660 shares during the period. Samsara Biocapital LLC grew its position in Alumis by 47.0% in the 2nd quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock valued at $14,404,000 after purchasing an additional 1,534,872 shares during the period. Finally, Cormorant Asset Management LP increased its stake in Alumis by 69.3% during the 4th quarter. Cormorant Asset Management LP now owns 3,635,596 shares of the company’s stock valued at $35,483,000 after purchasing an additional 1,488,200 shares in the last quarter.

Analysts Set New Price Targets

ALMS has been the topic of several research reports. Wall Street Zen downgraded shares of Alumis from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Citigroup reissued a “buy” rating on shares of Alumis in a research report on Tuesday, May 19th. Morgan Stanley reaffirmed an “overweight” rating and issued a $39.00 price target on shares of Alumis in a research report on Friday, May 15th. Wells Fargo & Company lifted their price target on Alumis from $49.00 to $51.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alumis in a report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $40.30.

Alumis Price Performance

ALMS opened at $28.25 on Friday. The company has a market capitalization of $3.60 billion, a price-to-earnings ratio of -14.27 and a beta of -0.73. The firm’s fifty day moving average price is $25.08 and its two-hundred day moving average price is $25.12. Alumis Inc. has a 1 year low of $3.76 and a 1 year high of $31.35.

Alumis (NASDAQ:ALMS) last posted its earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.01). Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%.The firm had revenue of $1.74 million during the quarter, compared to the consensus estimate of $2.10 million. As a group, equities analysts anticipate that Alumis Inc. will post -2.87 EPS for the current year.

Insiders Place Their Bets

In other Alumis news, insider Sanam Pangali sold 5,000 shares of the company’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $28.00, for a total value of $140,000.00. Following the completion of the sale, the insider directly owned 11,111 shares of the company’s stock, valued at approximately $311,108. This represents a 31.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 33.70% of the company’s stock.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.